Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sagimet Biosciences Inc. - Series A Common Stock (NQ: SGMT )

4.930 +0.170 (+3.57%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sagimet Biosciences Inc. - Series A Common Stock

< Previous 1 2 3 Next >
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
From Sagimet Biosciences Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024
SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET 
From Sagimet Biosciences Inc.
Via GlobeNewswire
What's Going On With Sagimet Biosciences Stock On Thursday?
Sagimet Biosciences shared promising data from its FASCINATE-2 Phase 2b trial of denifanstat at the EASL Congress. 
Via Benzinga
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
Via Benzinga
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH 
From Sagimet Biosciences Inc.
Via GlobeNewswire
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024
SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024 
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
From Sagimet Biosciences Inc.
Via GlobeNewswire
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.